A novel regulatory T cell-based therapy in development for the treatment of rheumatoid arthritis and hidradenitis suppurativa.
An autologous (using the patient’s own cells) Treg cell therapy to target proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.
An effector T Cell-modulating biologic for autoimmune diseases.
SBT-11-5301 is a biologic designed to eliminate highly activated effector T cells (Teff) that are dominant in autoimmune and inflammatory disease.
A novel regulatory T cell-based therapy in development for the treatment of neuroinflammatory diseases.
Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.
In partnership with:
Includes programs previously under the Sonoma Bio 7200 series.
To learn more about our partnership with Regeneron, read our Press Release.
A novel regulatory T cell-based therapy in development for the treatment of rheumatoid arthritis and hidradenitis suppurativa.
An autologous (using the patient’s own cells) Treg cell therapy to target proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.
A novel regulatory T cell-based therapy in development for the treatment of rheumatoid arthritis and hidradenitis suppurativa.
An autologous (using the patient’s own cells) Treg cell therapy to target proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.
An effector T Cell-modulating biologic for autoimmune diseases.
SBT-11-5301 is a biologic designed to eliminate highly activated effector T cells (Teff) that are dominant in autoimmune and inflammatory disease.
A novel regulatory T cell-based therapy in development for the treatment of neuroinflammatory diseases.
Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.
In partnership with:
Includes programs previously under the Sonoma Bio 7200 series.
To learn more about our partnership with Regeneron, read our Press Release.
Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.
In partnership with:
Includes programs previously under the Sonoma Bio 7200 series.
To learn more about our partnership with Regeneron, read our Press Release.
Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.
In partnership with:
Includes programs previously under the Sonoma Bio 7200 series.
To learn more about our partnership with Regeneron, read our Press Release.
Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.
In partnership with:
Includes programs previously under the Sonoma Bio 7200 series.
To learn more about our partnership with Regeneron, read our Press Release.
We are always looking for the right academic and industry partners.
